Provided by Tiger Fintech (Singapore) Pte. Ltd.

Kymera Therapeutics, Inc.

40.62
-0.2300-0.56%
Post-market: 40.620.00000.00%16:14 EDT
Volume:840.55K
Turnover:33.84M
Market Cap:2.85B
PE:-13.05
High:40.91
Open:40.67
Low:39.54
Close:40.85
52wk High:53.27
52wk Low:19.45
Shares:70.16M
Float Shares:46.72M
Volume Ratio:1.94
T/O Rate:1.80%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-3.1127
EPS(LYR):-2.9830
ROE:-32.17%
ROA:-19.47%
PB:3.62
PE(LYR):-13.62

Loading ...

Calendar of U.S. Earnings Expected in the Week Ahead

Dow Jones
·
Yesterday

Kymera Therapeutics Inc. to Report Second Quarter 2025 Financial Results

Reuters
·
Aug 04

Kymera Therapeutics initialed with Early-Stage Biotech at Goldman Sachs

TIPRANKS
·
Jul 15

When the market’s hot, go where it’s not: Biotech’s position of opportunity for FY26

LiveWire
·
Jul 15

Morgan Stanley Assumes Coverage of Kymera Therapeutics (KYMR) Stock with Overweight Rating

Insider Monkey
·
Jul 10

Brookline Capital Markets Sticks to Their Buy Rating for Kymera Therapeutics (KYMR)

TIPRANKS
·
Jul 07

Kymera Therapeutics: Buy Rating Backed by Innovative Drug Discovery and Strategic Partnerships

TIPRANKS
·
Jul 03

Kymera Therapeutics assumed with an Overweight at Morgan Stanley

TIPRANKS
·
Jul 03

BVF Partners Reports Acquisition of Kymera Therapeutics Common Shares

Reuters
·
Jul 02

Kymera Therapeutics management to meet with B. Riley

TIPRANKS
·
Jul 01

Baker Bros. Advisors LP Reports Acquisition of Common Shares in Kymera Therapeutics Inc

Reuters
·
Jul 01

Kymera Therapeutics price target raised to $54 from $51 at BofA

TIPRANKS
·
Jun 30

Kymera Therapeutics Held Annual Shareholders Meeting

Reuters
·
Jun 28

Kymera Therapeutics Is Maintained at Outperform by Oppenheimer

Dow Jones
·
Jun 28

BUZZ-U.S. STOCKS ON THE MOVE-Estee Lauder, TC Energy, Cancer test makers

Reuters
·
Jun 28

Kymera Therapeutics 5.043M share Spot Secondary priced at $44.00

TIPRANKS
·
Jun 27

BRIEF-Kymera Therapeutics Announces Pricing Of $250 Million Public Offering

Reuters
·
Jun 27

Kymera Therapeutics Is Maintained at Overweight by Wells Fargo

Dow Jones
·
Jun 26

TD Cowen Keeps Their Buy Rating on Kymera Therapeutics (KYMR)

TIPRANKS
·
Jun 26

Truist Financial Remains a Buy on Kymera Therapeutics (KYMR)

TIPRANKS
·
Jun 26